Explore the vast range of titles available.

Pseudomonas aeruginosa, an ESKAPE pathogen causes many fatal clinical diseases in humans across the globe. Despite an increase in clinical instances of Pseudomonas infection, there is currently no effective vaccine or treatment available. The major membrane protein candidate of the P. aeruginosa bacterial cell is known to be a critical component for cellular bacterial susceptibility to antimicrobial peptides and survival inside the host organisms. Therefore, the current computational study aims to examine P. aeruginosa’s major membrane protein, OprF, and OprI, in order to design linear B-cell, cytotoxic T-cell, and helper T-cell peptide-based vaccine constructs. Utilizing various immune-informatics tools and databases, a total of two B-cells and twelve T-cells peptides were predicted. The final vaccine design was simulated to generate a high-quality three-dimensional structure, which included epitopes, adjuvant, and linkers. The vaccine was shown to be nonallergenic, antigenic, soluble, and had the best biophysical properties. The vaccine and Toll-like receptor 4 have a strong and stable interaction, according to protein-protein docking and molecular dynamics simulations. Additionally, in silico cloning was employed to see how the developed vaccine expressed in the pET28a (+) vector. Ultimately, an immune simulation was performed to see the vaccine efficacy. In conclusion, the newly developed vaccine appears to be a promising option for a vaccine against P. aeruginosa infection.

Rotavirus (RV) is a common double-stranded RNA virus that causes diarrheal disease in young children. The prevalent species, Rotavirus A (RVA), is responsible for over 90% of human RV infections. With significant morbidity and mortality, this pathogen poses a serious global health challenge, particularly in underdeveloped countries. This study presents an immunoinformatics approach for designing an mRNA vaccine based on a multi-peptide construct to elicit robust immune responses against RVA. The VP4 was analyzed from 40 sequences using phylogenetic analysis. Prediction of cytotoxic (CTL) and helper T cell (HTL) epitopes was performed and validated. The 17 high-conservancy CTL/HTL epitopes were selected for vaccine construction. The mRNA vaccine based on multi-peptide was engineered with human beta-defensin 3 (hBD3) adjuvant and linkers to enhance immunogenicity. The designed mRNA vaccine product exhibited favorable physicochemical properties and was predicted to be a probable antigen, non-allergenic, and non-toxic. 2D and 3D structure validation demonstrated the quality of the model. Molecular docking with Toll-like receptor 2/3 (TLR2/3) indicated favorable interaction, and peptide docking with MHC-I/II alleles showed strong binding affinities and have significant Residue-Residue interactions. Simulation of immune responses revealed potent B-cell and T-cell activities, macrophage responses, and significant cytokine synthesis. Molecular dynamics simulation (MDS) confirmed the structural stability of the TLR3-vaccine complex, and MHC-peptide in 200ns and STQFTDFVSLNSLRF peptide have shown good interaction with MHC molecule. In addition, the MM/GBSA analysis yielded a binding free energy of − 89.77 kcal/mol, indicating a strong and stable interaction between the vaccine construct and the target receptor. Codon optimization and mRNA secondary structure prediction were carried out for efficient translation. Additionally, population coverage analysis indicated the vaccine’s effectiveness worldwide with 100% value. Overall, this study showcases a promising immunoinformatics approach for designing an mRNA vaccine based on a multi-peptide construct targeting RVA. The findings support the potential of this vaccine design to elicit robust and widespread immune responses against RVA infection, paving the way for future vaccine development strategies and this study needs experimental validation.

The spike glycoprotein is a key factor in the infection cycle of SARS-CoV-2, as it mediates both receptor recognition and membrane fusion by the virus. Therefore, in this study, we aimed to design a multi-peptide conjugate vaccine against SARS-CoV-2, targeting the early stages of the virus's life cycle. We used iBoost technology, which is designed to induce immune responses against low- or non-immunogenic epitopes. We selected six peptide sequences, each representing a key domain of the spike protein (i.e., receptor binding domain (RBM), subdomain 1 (SD1), subdomain 2 (SD2), S1/S2, fusion peptide and the S2’ sequences (FP + S2’), heptad repeat 1 (HR1)). Immunization studies in mice displayed targeted humoral and cellular immune responses against specific peptides of the spike protein simultaneously, while inducing cross-protection against the Delta and Omicron coronavirus variants. Moreover, vaccinated hamsters challenged with SARS-CoV-2 elicited high antibody levels against key peptides, induced early neutralizing antibody responses and resulted in less weight loss compared to controls. This highlights the potential for improving viral control and disease outcomes when utilizing this strategy. Therefore, by using iBoost technology in conjunction with our peptide design strategy, we were able to successfully target non-immunodominant regions in the spike protein while activating both arms of the adaptive immune system.

We have previously shown that lyophilized mixtures of six- and twelve-melanoma peptide vaccines retain stability, purity, and amino acid sequence identity for up to five years when stored at -80 °C. However, this temperature requirement presents a significant obstacle to storage and distribution of vaccines for low-resource environments. Thus, we examined the stability of these peptides over a range of temperatures for varying durations of time. When stored at +4 °C or at room temperature for up to three months, 17 of the 18 peptides remained stable. The only change for the remaining peptide was an increase in an oxidized methionine residue. The results presented in this report support broadening the accessibility of these and other peptide-based vaccines to resources-limited communities.

Triple-negative breast cancer (TNBC) is associated with a poor prognosis due to high recurrence rates and a lack of targeted therapies. Significant challenges in developing efficacious TNBC cancer vaccines are tumor antigen heterogeneity and the risk of antigen-negative variant escape, where target antigen-negative tumor cells can emerge, evading single-antigen vaccine-induced immunity, and drive tumor growth. To address this, we developed TNBCvax, a multi-antigen, multi-peptide vaccine targeting three tumor-associated antigens overexpressed in TNBC: TOP2A, HIF-1α and IGF-1R. The immune preventive effect of TNBCvax was evaluated in both a syngeneic M6 TNBC tumor graft model and the C3(1)/Tag genetically engineered mouse model of TNBC. Our findings demonstrate that TNBCvax significantly reduced tumor development and progression, compared to single-antigen vaccines. TNBCvax induced a robust tumor-associated antigen-specific immune response as evidenced by the increased infiltration of CD3+ T cells, particularly CD8+ T cells, with elevated levels of granzyme B and tumor necrosis factor alpha (TNF-α). TNBCvax was well-tolerated with no significant major organ toxicities, supporting its potential safety in the clinic. In conclusion, TNBCvax offers a promising immunopreventive strategy against TNBC by targeting multiple antigens to provide a broader and more robust immune coverage against TNBC antigens while reducing the risk of antigen-negative variant escape.

Background: Human fibroblast-derived multi-peptide factors (MPFs) promote wound repair by playing crucial roles in cell recruitment, adhesion, attachment, migration, and proliferation. Methods: Cultured human dermal fibroblasts (HDFs) were directly treated with non-contact low- and high-energy nitrogen plasma and further cultured in various conditioned media. Cell proliferation and wound-healing properties were evaluated. Results: In Opti-modified Eagle's medium + GlutaMAX culture, reduced HDF viability was observed 24 h after 2- J/pulse plasma treatment and 12 and 24 h after 3-J/pulse treatment. Meanwhile, in dermal fibroblast-conditioned medium (DFCM) containing MPF culture, reduced HDF viability was observed only 24 h after 3-J/pulse treatment. Under DFCM-MPF culture, the wound area percentage was significantly decreased after 12 and 24 h in untreated HDFs; at 9, 12, and 24 h after 1-J/pulse plasma treatment; at 3, 6, 9, 12, and 24 h after 2-J/pulse plasma treatment; and at 9, 12, and 24 h after 3-J/pulse plasma treatment. Greater migration of HDFs with or without plasma treatment was found in DFCM-MPFs than in other conditioned media. Conclusion: Low-energy nitrogen plasma treatment promotes HDF proliferation and wound repair. DFCM-MPFs enhanced cell proliferation and improved the wound healing properties of HDFs treated with low- and high-energy plasma. Keywords: human dermal fibroblasts, multi-peptide factors, dermal fibroblast-conditioned media, plasma, nitrogen, cell proliferation, wound healing, cell migration

Antigenic domain A is a highly conserved unit on envelope protein E2 of classical swine fever virus (CSFV). It was found that mutant E2 containing only unit A, with the unit BC deleted, provided immunized pigs with complete protection against the lethal challenge. In this study, six overlapping peptides (A1–A6) covering this unit were synthesized and conjugated to bovine serum albumin (BSA). Two candidate multi-peptide-vaccines (MPVs) using aluminum adjuvant successfully induced potent immunity against CSFV in pigs. Although both candidate MPVs failed to provide complete protection, they showed better protective activity than that induced by C-strain. Subsequently, neutralizing epitopes in unit A were identified using a panel of peptide-vaccines (PVs). Six candidate peptide-vaccines (PV-An, n = 1–6) were separately given to six groups of pigs. Among these candidates, PV-A2 and PV-A6 exhibited the most potent protective activity, while the other four showed weaker or almost no effects. Moreover, the polyclonal antibodies induced by PV-A2 and PV-A6 were capable of neutralizing C-strain virus at the dilution 1:16 in vitro. Thus, two principal sequential neutralizing determinants covered by peptide A2 (aa792–814) and A6 (aa844–865) were demonstrated to exist in the antigenic domain A, and can be recruited in developing new effective “marker vaccine” against CSFV.

Our previous study proposed a protective multi-peptide-vaccine (MPV) with Freund's adjuvant against classical swine fever virus (CSFV). In this study, another candidate MPV, using aluminum adjuvant, was further examined. All immunized pigs kept healthy during the experimental period, while the control group rapidly showed clinical symptoms and died. Moreover, anti-sera from MPV-immunized pigs could interact with peptides involved in the MPV, in contrast to anti-sera from non-immunized or infected ones. This property permits MPV-immunized pigs to be easily differentiated from infected ones with simple serological method. Therefore, this new MPV is suitable to act as a candidate marker vaccine against CSFV.

Henry A. Giroux challenges the contemporary politics of cynicism by addressing a number of issues including the various attacks on cultural politics, the multicultural discourses of academia, the corporate attack on higher education, and the cultural politics of the Disney empire.